Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketorolac for GTPase inhibition in ovarian cancer
NCT02470299Completed
- Sponsor
- New Mexico Cancer Research Alliance
- Start
- Oct 2015
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) comparing Ketorolac with Placebo (2 arms). Primary endpoint: Ketorolac inhibition of GTPase activity at 4 weeks. Started Oct 2015; status: completed.
02
Drugs
ketorolac
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT02470299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02470299.